PITTSBURGH - s4story -- SNS Research has released its latest market report, "Psoriasis Drugs Market: 2025 – 2035 – Opportunities, Challenges, Strategies & Forecasts," detailing the competitive, clinical, and commercial dynamics shaping the global psoriasis therapeutics landscape through the next decade.

Global spending on psoriasis drugs is projected to approach 20 Billion dollars by the end of 2025, driven by rising disease prevalence, broader diagnosis, and a sustained shift toward high-efficacy immunology agents. The report examines how manufacturers are recalibrating strategy as treatment expectations continue to rise and patient preference shifts toward convenient, non-injectable options.

The 214-page study includes coverage of 50-plus development pipeline candidates and profiles 66 companies operating across biologics, oral systemics, and advanced topical modalities. The analysis outlines key factors that will determine market positioning through 2035, with emphasis on late-stage development trends, therapeutic class momentum, and evolving competitive pressures.

More on S For Story

• Arcuri Group Announces Long‑Term Partnership with WakeMed Health & Hospitals to Deliver Situational Awareness and De‑escalation Training
• National Digital Magazine to Spotlight Women Over 50 and Canada's Tourism Economy
• Seth Neblett's Mothership Connected: Focuses on P-Funk's Women as Mothership Celebrates 50 Years
• At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
• Nola Blue announces the forthcoming autobiography of Trudy Lynn

Key Findings in the Report:

• Biologics remain the market's central growth driver. Interleukin inhibitors, particularly IL-17 and IL-23 agents such as Skyrizi and Tremfya, continue to anchor the category through strong efficacy and durable clearance rates.
• ​Oral immunomodulators represent the next major commercial opportunity. Pipeline concentration on TYK2 and other targeted pathways reflects increasing demand for biologic-level outcomes without injections.
• Biosimilar impact remains limited in the United States. Access constraints, contracting dynamics, and ongoing litigation have slowed adoption across TNF and IL-12/23 classes, extending the lifecycle of reference biologics.
• Innovation is expanding across systemics and topicals. Selective JAK inhibitors, next-generation PDE4 agents, and advanced topical combinations are gaining traction as developers seek to improve adherence and long-term outcomes.
• Industry consolidation continues to intensify. Acquisitions and platform partnerships underscore the strategic value of robust immunology portfolios and diversified modality positions.

The report concludes that long-term market leadership will depend on disciplined integration of clinical development progress with commercial execution, particularly in categories where convenience, durability of response, and differentiation remain decisive.

More on S For Story

• Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
• OurSeniors.net Magazine Marks 10 Years: Improving Senior Life with All-Inclusive Resources
• War, Peace, and Everything That Destroys You: The Novels of Leo Tolstoy, Reimagined
• VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
• NEW BOOK: Beyond Capitalism and Communism: The Case for Egalitarian Deliberative Democracy

The full "Psoriasis Drugs 2025 Market" report, is available at: https://www.snsresearch.com/psoriasis-drugs-market-report-2025.html

About SNS Research:
SNS Research is a U.S. based intelligence firm focused on the healthcare and pharmaceutical sectors. The company delivers independent market analysis, pipeline evaluations, and evidence-driven forecasts used by biopharmaceutical manufacturers, investors, government agencies, academic institutions, and regulatory organizations.

For enquiries, quotes, or additional information: info@snsintel.com